Our Commitment to Patients
With Progesterone Receptor Positive (PR+) Cancers
At Context Therapeutics, we are passionate about improving health and committed to helping people with cancer. Our initial clinical focus is on developing our investigational oral progesterone receptor antagonist, Apristor, in PR+ rare ovarian cancer, endometrial cancer, and breast cancer.
Rare Ovarian Cancers
Ovarian cancer is comprised of several subtypes based on biophysical and molecular determinants. Subtypes that respond to progesterone signaling are typically rare and are often associated with worse prognosis. These subtypes include Low Grade Serous Ovarian Cancer (LGSOC) and Granulosa Cell Tumor of the Ovary.
There are approximately 750,000 metastatic breast cancer patients worldwide. Of those patients, 50-70% have breast cancer that is driven by aberrant hormone signaling via activation of progesterone receptor (PR) and/or estrogen receptor (ER) signaling.